Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy

Publisher： Karger

E-ISSN： 1421-9662|118|3|162-164

ISSN： 0001-5792

Source： Acta Haematologica, Vol.118, Iss.3, 2007-09, pp. : 162-164

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 127, Iss. 1, 2011-11 ,pp. : 56-59

Karger

Access to resources Recommend Favorite

Nilotinib after imatinib first‐line: a real‐life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 3, 2018-02 ,pp. : 356-364

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

By Yood Marianne Ulcickas   Oliveria Susan A.   Cziraky Mark   Hirji Ishan   Hamdan Muhammad   Davis Catherine  

Current Medical Research and Opinion, Vol. 28, Iss. 2, 2012-02 ,pp. : 213-219

Informa Healthcare

Access to resources Recommend Favorite

More about Imatinib and Nilotinib Combination Therapy in Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-09 ,pp. : 18-19

Karger

Access to resources Recommend Favorite

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib - a retrospective chart review analysis

By Griffin James D.  

Current Medical Research and Opinion, Vol. 29, Iss. 6, 2013-06 ,pp. : 623-631

Informa Healthcare

Access to resources Recommend Favorite